Current Understanding of Urachal Adenocarcinoma and Management Strategy

Mélanie Claps, Marco Stellato, Emma Zattarin, Alessia Mennitto, Pierangela Sepe, Valentina Guadalupi, Roberta Mennitto, Filippo G. M. de Braud, Elena Verzoni, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review


PURPOSE OF REVIEW: The aim of this review is to sum up the state of the art of urachal carcinoma (UC) in order to easily guide clinicians. RECENT FINDINGS: UC is a rare and aggressive disease with consequent few data about diagnosis and treatment. Dates are mainly based on retrospective trial and case reports with limited prospective trial. Clinical presentation is not specific, often with urinary symptoms. Diagnosis is mainly based on CT scan and MRI, useful to evaluate local invasion and nodal status and to detect the presence of distant metastases. Therefore, biopsy is needed to obtain histological confirmation. Surgery is the gold standard for localized disease, while different chemotherapy schemes have been used in metastatic setting. Novel findings based on mutational analysis of the tumor include the use of biological treatment, such as cetuximab, and immunotherapy, such as atezolizumab, with satisfactory responses, suggesting that personalized treatment could be the most suitable option for UC.
Original languageEnglish
JournalCurrent Oncology Reports
Issue number1
Publication statusPublished - Jan 1 2020


Dive into the research topics of 'Current Understanding of Urachal Adenocarcinoma and Management Strategy'. Together they form a unique fingerprint.

Cite this